Top 5 Drug Type | Count |
---|---|
Small molecule drug | 16 |
Synthetic peptide | 1 |
Enzyme | 1 |
Immunoglobulin | 1 |
Interferons | 1 |
Target |
Mechanism vWFCP modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date09 Nov 2023 |
Target- |
Mechanism Immunomodulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date23 Aug 2017 |
Target |
Mechanism GAG modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. KR |
First Approval Date09 Jan 2012 |
Start Date10 May 2024 |
Sponsor / Collaborator Cybin IRL Ltd. [+2] |
Start Date02 Apr 2024 |
Sponsor / Collaborator |
Start Date02 Aug 2022 |
Sponsor / Collaborator Cybin IRL Ltd. [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Paclitaxel ( Tubulin ) | Uterine Neoplasms More | Approved |
Idursulfase beta ( GAG ) | Mucopolysaccharidosis II More | Approved |
Betaxolol Hydrochloride ( β1-adrenergic receptor ) | Essential Hypertension More | Approved |
Amifostine ( TNSALP ) | Chemotherapy-induced damage More | Approved |
Interferon gamma-1b ( IFNGR1 ) | Granulomatous Disease, Chronic More | Approved |